Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Climb Bio, Inc.CLYM · Entity 5064 | Chief Financial Officer | January 06, 2026 | January 08, 2026 |
| ImmunoGen, Inc.IMGN · Entity 94428 | SVP AND CFO | May 20, 2022 | December 27, 2022 |
| Mural Oncology plcMURA · Entity 72153 | Director | August 14, 2024 | August 15, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Climb Bio, Inc.
Report date January 06, 2026 · Filed January 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.81 · Expires 2036-01-05 | Direct | 142,500 |
Reported balance
After 2026-01-06 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-06 · Grant · Acquired 142,500 · Balance 142,500 F1: This option was granted on January 6, 2026 (the "Grant Date"). The shares underlying the option are scheduled to vest with respect to 25% of the shares on the first anniversary of the Grant Date and the remainder are scheduled to vest in 36 equal monthly installments through January 6, 2030, subject to the Reporting Person's continued service. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was granted on January 6, 2026 (the "Grant Date"). The shares underlying the option are scheduled to vest with respect to 25% of the shares on the first anniversary of the Grant Date and the remainder are scheduled to vest in 36 equal monthly installments through January 6, 2030, subject to the Reporting Person's continued service.
ImmunoGen, Inc.
Report date May 20, 2022 · Filed December 27, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.74 · Expires 2030-07-20 | Direct | 41,250 |
Reported balance
After 2022-05-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-05-20 · Grant · Acquired 41,250 · Balance 41,250 F1: On July 20, 2020, the reporting person was granted an option to purchase 165,000 shares of common stock. The option vests in installments upon the satisfaction of certain performance criteria. On May 20, 2022, certain performance criteria were met, resulting in the vesting of 25% of the performance stock option award. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.74 · Expires 2030-07-20 | Direct | 123,750 |
Reported balance
After 2022-11-14 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-11-14 · Grant · Acquired 82,500 · Balance 123,750 F2: On July 20, 2020, the reporting person was granted an option to purchase 165,000 shares of common stock. The option vests in installments upon the satisfaction of certain performance criteria. On November 14, 2022, certain performance criteria were met, resulting in the vesting of 50% of the performance stock option award. |
Filing footnotes · ownership attribution and instrument terms
F1: On July 20, 2020, the reporting person was granted an option to purchase 165,000 shares of common stock. The option vests in installments upon the satisfaction of certain performance criteria. On May 20, 2022, certain performance criteria were met, resulting in the vesting of 25% of the performance stock option award.
F2: On July 20, 2020, the reporting person was granted an option to purchase 165,000 shares of common stock. The option vests in installments upon the satisfaction of certain performance criteria. On November 14, 2022, certain performance criteria were met, resulting in the vesting of 50% of the performance stock option award.
Mural Oncology plc
Report date August 14, 2024 · Filed August 15, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 10,000 |
Reported balance
After 2024-08-14 transaction · row 1
1 source rowRow 1 · 2024-08-14 · Purchase · Acquired 10,000 · Balance 10,000 F1: The price reported in column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.17 to $3.25. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.17 to $3.25. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Cerevel Therapeutics Holdings, Inc.
Report date August 01, 2024 · Filed August 05, 2024
Section 16 reporting ended · disclosed 2024-08-05. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2024-08-01 transaction · row 1
1 source rowRow 1 · 2024-08-01 · Disposition to issuer · Disposed 16,913 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated December 6, 2023, by and among AbbVie Inc. ("Parent"), Symphony Harlan LLC, Symphony Harlan Merger Sub Inc. ("Merger Sub") and Cerevel Therapeutics Holdings, Inc. ("Issuer"), on August 1, 2024 (the "Effective Time"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock was cancelled and converted into the right to receive $45.00 in cash (the "Merger Consideration"), without interest. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2024-08-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-08-01 · Disposition to issuer · Disposed 124,168 · Balance 0 F2: At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of common stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2024-08-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-08-01 · Disposition to issuer · Disposed 81,065 · Balance 0 F3: At the Effective Time, (a) 50% of each outstanding award of restricted stock units ("RSUs") that was granted on or after December 6, 2023 was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the aggregate number of shares underlying such RSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement, and (b) the remaining 50% was assumed by Parent and converted into RSUs with respect to shares of the Parent's common stock in accordance with the terms of the Merger Agreement. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated December 6, 2023, by and among AbbVie Inc. ("Parent"), Symphony Harlan LLC, Symphony Harlan Merger Sub Inc. ("Merger Sub") and Cerevel Therapeutics Holdings, Inc. ("Issuer"), on August 1, 2024 (the "Effective Time"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock was cancelled and converted into the right to receive $45.00 in cash (the "Merger Consideration"), without interest.
F2: At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of common stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement.
F3: At the Effective Time, (a) 50% of each outstanding award of restricted stock units ("RSUs") that was granted on or after December 6, 2023 was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the aggregate number of shares underlying such RSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement, and (b) the remaining 50% was assumed by Parent and converted into RSUs with respect to shares of the Parent's common stock in accordance with the terms of the Merger Agreement.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 06, 2026 Filed Jan 8, 2026 16:05 UTC | Climb Bio, Inc. CLYM · Entity 5064 | GrantStock Option (Right to Buy) · Derivative | 142,500 | $0.00 Strike: $3.81 | $0.00 |
DisclosureSEC source: 0001193125-26-007665 · ownership.xml · derivative · entry 1 ALTSCHULLER Susan · CIK 0001817988 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 142,500 Underlying: Common Stock · 142,500 shares Expires 2036-01-05 F1 · derivative.exercise_date: This option was granted on January 6, 2026 (the "Grant Date"). The shares underlying the option are scheduled to vest with respect to 25% of the shares on the first anniversary of the Grant Date and the remainder are scheduled to vest in 36 equal monthly installments through January 6, 2030, subject to the Reporting Person's continued service. Read SEC document |
| October 01, 2025 Filed Oct 1, 2025 17:52 UTC | Climb Bio, Inc. CLYM · Entity 5064 | GrantStock Option (Right to Buy) · Derivative | 600,000 | $0.00 Strike: $1.97 | $0.00 |
DisclosureSEC source: 0001193125-25-227099 · ownership.xml · derivative · entry 1 ALTSCHULLER Susan · CIK 0001817988 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 600,000 Underlying: Common Stock · 600,000 shares Expires 2035-09-30 F1 · derivative.exercise_date: This option was granted on October 1, 2025 (the "Grant Date"). The shares underlying the option are scheduled to vest with respect to 25% of the shares on the first anniversary of the Grant Date, and the remainder are scheduled to vest in 36 equal monthly installments through October 1, 2029, subject to the Reporting Person's continued service. Read SEC document |
| August 14, 2024 Filed Aug 15, 2024 16:15 UTC | Mural Oncology plc MURA · Entity 72153 | PurchaseOrdinary Shares | 10,000 | $3.21 | $32,071.00 |
DisclosureSEC source: 0000950170-24-097576 · ownership.xml · nonDerivative · entry 1 ALTSCHULLER Susan · CIK 0001817988 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 F1 · price: The price reported in column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.17 to $3.25. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 01, 2024 Filed Aug 5, 2024 16:26 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | Disposition to issuerRestricted Stock Units · Derivative | 81,065 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-090813 · ownership.xml · derivative · entry 3 ALTSCHULLER Susan · CIK 0001817988 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 81,065 shares Expires not disclosed F3 · derivative.exercise_price: At the Effective Time, (a) 50% of each outstanding award of restricted stock units ("RSUs") that was granted on or after December 6, 2023 was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the aggregate number of shares underlying such RSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement, and (b) the remaining 50% was assumed by Parent and converted into RSUs with respect to shares of the Parent's common stock in accordance with the terms of the Merger Agreement. F3 · derivative.exercise_date: At the Effective Time, (a) 50% of each outstanding award of restricted stock units ("RSUs") that was granted on or after December 6, 2023 was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the aggregate number of shares underlying such RSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement, and (b) the remaining 50% was assumed by Parent and converted into RSUs with respect to shares of the Parent's common stock in accordance with the terms of the Merger Agreement. F3 · derivative.expiration_date: At the Effective Time, (a) 50% of each outstanding award of restricted stock units ("RSUs") that was granted on or after December 6, 2023 was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the aggregate number of shares underlying such RSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement, and (b) the remaining 50% was assumed by Parent and converted into RSUs with respect to shares of the Parent's common stock in accordance with the terms of the Merger Agreement. Read SEC document |
| August 01, 2024 Filed Aug 5, 2024 16:26 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | Disposition to issuerStock Option (Right to Buy) · Derivative | 124,168 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-090813 · ownership.xml · derivative · entry 2 ALTSCHULLER Susan · CIK 0001817988 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 124,168 shares Expires not disclosed F2 · derivative.exercise_price: At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of common stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement. F2 · price: At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of common stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement. F2 · derivative.exercise_date: At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of common stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement. F2 · derivative.expiration_date: At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of common stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement. Read SEC document |
| August 01, 2024 Filed Aug 5, 2024 16:26 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | Disposition to issuerCommon Stock | 16,913 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-090813 · ownership.xml · nonDerivative · entry 1 ALTSCHULLER Susan · CIK 0001817988 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated December 6, 2023, by and among AbbVie Inc. ("Parent"), Symphony Harlan LLC, Symphony Harlan Merger Sub Inc. ("Merger Sub") and Cerevel Therapeutics Holdings, Inc. ("Issuer"), on August 1, 2024 (the "Effective Time"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock was cancelled and converted into the right to receive $45.00 in cash (the "Merger Consideration"), without interest. Read SEC document |
| May 30, 2024 Filed Jun 3, 2024 10:11 UTC | Mural Oncology plc MURA · Entity 72153 | GrantStock Option (right to buy) · Derivative | 8,462 | $3.35 Strike: $3.35 | $28,347.70 |
DisclosureSEC source: 0000950170-24-067702 · ownership.xml · derivative · entry 1 ALTSCHULLER Susan · CIK 0001817988 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,462 Underlying: Ordinary Shares · 8,462 shares Expires 2034-05-29 F1 · derivative.exercise_date: This option was granted on May 30, 2024. This option will vest in full upon the earlier of (i) the first anniversary of the date of the grant or (ii) the date of the next Annual Meeting, subject to the reporting person's continued service with the Issuer. Read SEC document |
| May 30, 2024 Filed Jun 5, 2024 16:08 UTC Amendment | Mural Oncology plc MURA · Entity 72153 | GrantStock Option (right to buy) · Derivative | 8,462 | $0.00 Strike: $3.35 | $0.00 |
DisclosureSEC source: 0000950170-24-069301 · ownership.xml · derivative · entry 1 ALTSCHULLER Susan · CIK 0001817988 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,462 Underlying: Ordinary Shares · 8,462 shares Expires 2034-05-29 F2 · price: This amendment to Form 4 is being filed solely to correct the price of the derivative security, which was previously reported as being $3.35 due to a scrivener's error. F1 · derivative.exercise_date: This option was granted on May 30, 2024. This option will vest in full upon the earlier of (i) the first anniversary of the date of the grant or (ii) the date of the next Annual Meeting, subject to the reporting person's continued service with the Issuer. Read SEC document |
| January 19, 2024 Filed Jan 23, 2024 17:51 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | GrantRestricted Stock Units · Derivative | 81,065 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-006706 · ownership.xml · derivative · entry 1 ALTSCHULLER Susan · CIK 0001817988 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,065 Underlying: Common Stock · 81,065 shares Expires not disclosed F1 · derivative.exercise_price: The shares reported in this transaction represent Restricted Stock Units ("RSUs") granted under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan (the "Plan"). Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs vest in four equal annual installments on each of January 19, 2025, January 19, 2026, January 19, 2027 and January 19, 2028, subject to the Reporting Person's continued service on each such vesting date. F1 · derivative.exercise_date: The shares reported in this transaction represent Restricted Stock Units ("RSUs") granted under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan (the "Plan"). Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs vest in four equal annual installments on each of January 19, 2025, January 19, 2026, January 19, 2027 and January 19, 2028, subject to the Reporting Person's continued service on each such vesting date. F1 · derivative.expiration_date: The shares reported in this transaction represent Restricted Stock Units ("RSUs") granted under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan (the "Plan"). Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs vest in four equal annual installments on each of January 19, 2025, January 19, 2026, January 19, 2027 and January 19, 2028, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| December 20, 2023 Filed Dec 21, 2023 20:12 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | SaleCommon Stock | 13,808 | $41.42 | $571,971.55 |
DisclosureSEC source: 0000950170-23-072368 · ownership.xml · nonDerivative · entry 2 ALTSCHULLER Susan · CIK 0001817988 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,913 F3 · kind: The Issuer has adopted a "sell-to-cover" policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $41.36 to $41.50. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 19, 2023 Filed Dec 21, 2023 20:12 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | Exercise / conversionRestricted Stock Units · Derivative | 30,721 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-23-072368 · ownership.xml · derivative · entry 3 ALTSCHULLER Susan · CIK 0001817988 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,721 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represented the contingent right to receive one share of the Issuer's common stock. F1 · kind: In order to mitigate the impact of Sections 280G and 4999 of the Internal Revenue Code of 1986, as amended, in connection with the transactions contemplated by the Agreement and Plan of Merger, dated as of December 6, 2023, by and among Cerevel Therapeutics Holdings, Inc. (the "Issuer"), AbbVie Inc., Symphony Harlan LLC and Symphony Harlan Merger Sub Inc., the restricted stock units ("RSUs") held by the Reporting Person vested in full on December 19, 2023, subject to certain repayment conditions in the event that the Reporting Person's employment terminates for any reason prior to the date the RSUs otherwise would vest. F1 · derivative.exercise_date: In order to mitigate the impact of Sections 280G and 4999 of the Internal Revenue Code of 1986, as amended, in connection with the transactions contemplated by the Agreement and Plan of Merger, dated as of December 6, 2023, by and among Cerevel Therapeutics Holdings, Inc. (the "Issuer"), AbbVie Inc., Symphony Harlan LLC and Symphony Harlan Merger Sub Inc., the restricted stock units ("RSUs") held by the Reporting Person vested in full on December 19, 2023, subject to certain repayment conditions in the event that the Reporting Person's employment terminates for any reason prior to the date the RSUs otherwise would vest. F1 · derivative.expiration_date: In order to mitigate the impact of Sections 280G and 4999 of the Internal Revenue Code of 1986, as amended, in connection with the transactions contemplated by the Agreement and Plan of Merger, dated as of December 6, 2023, by and among Cerevel Therapeutics Holdings, Inc. (the "Issuer"), AbbVie Inc., Symphony Harlan LLC and Symphony Harlan Merger Sub Inc., the restricted stock units ("RSUs") held by the Reporting Person vested in full on December 19, 2023, subject to certain repayment conditions in the event that the Reporting Person's employment terminates for any reason prior to the date the RSUs otherwise would vest. Read SEC document |
| December 19, 2023 Filed Dec 21, 2023 20:12 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | Exercise / conversionCommon Stock | 30,721 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-23-072368 · ownership.xml · nonDerivative · entry 1 ALTSCHULLER Susan · CIK 0001817988 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,721 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: In order to mitigate the impact of Sections 280G and 4999 of the Internal Revenue Code of 1986, as amended, in connection with the transactions contemplated by the Agreement and Plan of Merger, dated as of December 6, 2023, by and among Cerevel Therapeutics Holdings, Inc. (the "Issuer"), AbbVie Inc., Symphony Harlan LLC and Symphony Harlan Merger Sub Inc., the restricted stock units ("RSUs") held by the Reporting Person vested in full on December 19, 2023, subject to certain repayment conditions in the event that the Reporting Person's employment terminates for any reason prior to the date the RSUs otherwise would vest. F2 · price: Each RSU represented the contingent right to receive one share of the Issuer's common stock. Read SEC document |
| December 14, 2023 Filed Dec 18, 2023 16:30 UTC | Mural Oncology plc MURA · Entity 72153 | GrantStock Option (right to buy) · Derivative | 15,021 | $0.00 Strike: $3.61 | $0.00 |
DisclosureSEC source: 0000950170-23-071107 · ownership.xml · derivative · entry 1 ALTSCHULLER Susan · CIK 0001817988 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,021 Underlying: Ordinary Shares · 15,021 shares Expires 2033-12-13 F1 · derivative.exercise_date: This option was granted on December 14, 2023. This option shall vest over three years in twelve equal quarterly installments on each quarterly anniversary of October 31, 2023, subject to the reporting person's continued service with the Issuer. Read SEC document |
| June 01, 2023 Filed Jun 5, 2023 20:15 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | GrantRestricted Stock Units · Derivative | 30,721 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-23-026503 · ownership.xml · derivative · entry 2 ALTSCHULLER Susan · CIK 0001817988 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,721 Underlying: Common Stock · 30,721 shares Expires not disclosed F2 · derivative.exercise_price: The shares reported in this transaction represent Restricted Stock Units ("RSUs") granted under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The RSUs vest in four equal annual installments on each of June 1, 2024, June 1, 2025, June 1, 2026 and June 1, 2027, subject to the Reporting Person's continued service on each such vesting date. F3 · derivative.expiration_date: The RSUs vest in four equal annual installments on each of June 1, 2024, June 1, 2025, June 1, 2026 and June 1, 2027, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| June 01, 2023 Filed Jun 5, 2023 20:15 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | GrantStock Option (Right to Buy) · Derivative | 124,168 | $0.00 Strike: $32.55 | $0.00 |
DisclosureSEC source: 0000950170-23-026503 · ownership.xml · derivative · entry 1 ALTSCHULLER Susan · CIK 0001817988 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 124,168 Underlying: Common Stock · 124,168 shares Expires 2033-06-01 F1 · derivative.exercise_date: 25% of this option shall vest and become exercisable on June 1, 2024, with the remainder vesting in thirty-six (36) monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| November 14, 2022 Filed Dec 27, 2022 17:14 UTC | ImmunoGen, Inc. IMGN · Entity 94428 | GrantStock Option (Right to Buy) · Derivative | 82,500 | $0.00 Strike: $4.74 | $0.00 |
DisclosureSEC source: 0001415889-22-012991 · form4-12272022_101224.xml · derivative · entry 2 ALTSCHULLER Susan · CIK 0001817988 · SVP AND CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,750 Underlying: Common Stock · 82,500 shares Expires 2030-07-20 F2 · derivative.exercise_date: On July 20, 2020, the reporting person was granted an option to purchase 165,000 shares of common stock. The option vests in installments upon the satisfaction of certain performance criteria. On November 14, 2022, certain performance criteria were met, resulting in the vesting of 50% of the performance stock option award. Read SEC document |
| May 20, 2022 Filed Dec 27, 2022 17:14 UTC | ImmunoGen, Inc. IMGN · Entity 94428 | GrantStock Option (Right to Buy) · Derivative | 41,250 | $0.00 Strike: $4.74 | $0.00 |
DisclosureSEC source: 0001415889-22-012991 · form4-12272022_101224.xml · derivative · entry 1 ALTSCHULLER Susan · CIK 0001817988 · SVP AND CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,250 Underlying: Common Stock · 41,250 shares Expires 2030-07-20 F1 · derivative.exercise_date: On July 20, 2020, the reporting person was granted an option to purchase 165,000 shares of common stock. The option vests in installments upon the satisfaction of certain performance criteria. On May 20, 2022, certain performance criteria were met, resulting in the vesting of 25% of the performance stock option award. Read SEC document |
| February 04, 2022 Filed Feb 8, 2022 17:27 UTC | ImmunoGen, Inc. IMGN · Entity 94428 | GrantCommon Stock (right to buy) · Derivative | 361,568 | $5.32 Strike: $5.32 | $1,923,541.76 |
DisclosureSEC source: 0001179110-22-000926 · edgar.xml · derivative · entry 1 ALTSCHULLER Susan · CIK 0001817988 · SVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 361,568 Underlying: Common Stock · 361,568 shares Expires 2032-02-04 F1 · derivative.exercise_date: These options vest over a four-year period, with 25% of the shares vesting on the one year anniversary of the date of grant, and thereafter an additional 6.25% of the shares vesting on each succeeding quarterly anniversary of the date of grant. Read SEC document |
| February 05, 2021 Filed Feb 9, 2021 20:11 UTC | ImmunoGen, Inc. IMGN · Entity 94428 | GrantCommon Stock (right to buy) · Derivative | 163,798 | $7.69 Strike: $7.69 | $1,259,606.62 |
DisclosureSEC source: 0001179110-21-001496 · edgar.xml · derivative · entry 1 ALTSCHULLER Susan · CIK 0001817988 · SVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,798 Underlying: Common Stock · 163,798 shares Expires 2031-02-05 F1 · derivative.exercise_date: These options vest over a four-year period, with 25% of the shares vesting on the one year anniversary of the date of grant, and thereafter an additional 6.25% of the shares vesting on each succeeding quarterly anniversary of the date of grant. Read SEC document |
| July 20, 2020 Filed Jul 22, 2020 15:44 UTC | ImmunoGen, Inc. IMGN · Entity 94428 | GrantCommon Stock (right to buy) · Derivative | 300,000 | $4.74 Strike: $4.74 | $1,422,000.00 |
DisclosureSEC source: 0001179110-20-008407 · edgar.xml · derivative · entry 1 ALTSCHULLER Susan · CIK 0001817988 · SVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2030-07-20 F1 · derivative.exercise_date: These options vest over a four-year period, with 25% of the shares vesting on the one year anniversary of the date of grant, and thereafter an additional 6.25% of the shares vesting on each succeeding quarterly anniversary of the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.